{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:47:31Z","timestamp":1789663651625,"version":"4.0.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,23]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>VWF and FVIII levels after desmopressin, which mimic hemostatic response, are associated with the bleeding phenotype of type 1 VWD patients. Variability in VWF and FVIII response to hemostatic challenges may partly explain heterogeneity in bleeding phenotype of VWD patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000863","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T11:32:27Z","timestamp":1576236747000},"page":"4147-4154","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3769-9148","authenticated-orcid":false,"given":"Ferdows","family":"Atiq","sequence":"first","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette M.","family":"Sch\u00fctte","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes E. M.","family":"Looijen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Boender","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-2995","authenticated-orcid":false,"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Erasmus University Medical Center\u2013Sophia Children\u2019s Hospital, Rotterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-5759","authenticated-orcid":false,"given":"Jeroen","family":"Eikenboom","sequence":"additional","affiliation":[{"name":"Division of Thrombosis and Hemostasis, Department of Internal Medicine and"},{"name":"Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-334X","authenticated-orcid":false,"given":"Moniek P. M.","family":"de Maat","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J. H. A.","family":"Kruip","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-1371","authenticated-orcid":false,"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"issue":"21","key":"2019122311224947900_B1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2019122311224947900_B2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1160\/TH12-04-0244","article-title":"Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease","volume":"108","author":"de Wee","year":"2012","journal-title":"Thromb Haemost"},{"issue":"7","key":"2019122311224947900_B3","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1538-7836.2010.03864.x","article-title":"Health-related quality of life among adult patients with moderate and severe von Willebrand disease","volume":"8","author":"de Wee","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2019122311224947900_B4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/bloodadvances.2018017418","article-title":"Significant gynecological bleeding in women with low von Willebrand factor levels","volume":"2","author":"Lavin","year":"2018","journal-title":"Blood Adv"},{"issue":"22","key":"2019122311224947900_B5","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2017-05-782029","article-title":"Advances in the diagnosis and treatment of von Willebrand disease","volume":"130","author":"Sharma","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2019122311224947900_B6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16186","article-title":"How I manage severe von Willebrand disease","volume":"187","author":"Leebeek","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2019122311224947900_B7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"Atiq","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"2019122311224947900_B8","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1002\/ajh.25499","article-title":"BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease","volume":"94","author":"Atiq","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2019122311224947900_B9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/jth.12927","article-title":"CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease","volume":"13","author":"Sanders","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"26","key":"2019122311224947900_B10","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease","volume":"123","author":"Federici","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019122311224947900_B11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand disease","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb Haemost"},{"issue":"7","key":"2019122311224947900_B12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/jth.13696","article-title":"von Willebrand factor and inflammation","volume":"15","author":"Kawecki","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019122311224947900_B13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0049-3848(72)90056-4","article-title":"Rise of factor VIII after exercise and adrenaline infusion, measured by immunological and biological techniques","volume":"1","author":"Prentice","year":"1972","journal-title":"Thromb Res"},{"issue":"3","key":"2019122311224947900_B14","doi-asserted-by":"crossref","first-page":"e91687","DOI":"10.1371\/journal.pone.0091687","article-title":"Performance related factors are the main determinants of the von Willebrand factor response to exhaustive physical exercise","volume":"9","author":"van Loon","year":"2014","journal-title":"PLoS One"},{"issue":"14","key":"2019122311224947900_B15","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40265-017-0793-2","article-title":"Current and emerging options for the management of inherited von Willebrand disease","volume":"77","author":"Heijdra","year":"2017","journal-title":"Drugs"},{"issue":"20","key":"2019122311224947900_B16","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/bloodadvances.2018023713","article-title":"A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding","volume":"2","author":"Candy","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2019122311224947900_B19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/hae.13629","article-title":"Sports participation and physical activity in patients with von Willebrand disease","volume":"25","author":"Atiq","year":"2019","journal-title":"Haemophilia"},{"key":"2019122311224947900_B17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01610.x","article-title":"The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007)","volume":"14","author":"Federici","year":"2008","journal-title":"Haemophilia"},{"issue":"7","key":"2019122311224947900_B18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"Bod\u00f3","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019122311224947900_B20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2516.2007.01648.x","article-title":"Bleeding scores in inherited bleeding disorders: clinical or research tools?","volume":"14","author":"Tosetto","year":"2008","journal-title":"Haemophilia"},{"issue":"19","key":"2019122311224947900_B21","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood-2014-09-603241","article-title":"Von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease","volume":"125","author":"Sanders","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019122311224947900_B22","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"Castaman","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019122311224947900_B23","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2019122311224947900_B24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/aob.2017.12.05","article-title":"Von Willebrand disease in the United States: perspective from the Zimmerman program","volume":"3","author":"Flood","year":"2018","journal-title":"Ann Blood"},{"issue":"21","key":"2019122311224947900_B25","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood-2017-05-786699","article-title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","volume":"130","author":"Lavin","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2019122311224947900_B26","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"Flood","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019122311224947900_B27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V57.1.25.25","article-title":"Precipitating antibodies to factor VIII\/von Willebrand factor in von Willebrand\u2019s disease: effects on replacement therapy","volume":"57","author":"Mannucci","year":"1981","journal-title":"Blood"},{"issue":"5","key":"2019122311224947900_B28","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019122311224947900_B29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/hae.13165","article-title":"Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease","volume":"23","author":"Mannucci","year":"2017","journal-title":"Haemophilia"},{"issue":"3","key":"2019122311224947900_B30","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/hae.12670","article-title":"Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study","volume":"21","author":"van Galen","year":"2015","journal-title":"Haemophilia"},{"issue":"9","key":"2019122311224947900_B31","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2017.168617","article-title":"Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study","volume":"102","author":"van Galen","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"2019122311224947900_B32","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood.V74.6.1997.1997","article-title":"Consistency of responses to repeated DDAVP infusions in patients with von Willebrand\u2019s disease and hemophilia A","volume":"74","author":"Rodeghiero","year":"1989","journal-title":"Blood"},{"key":"2019122311224947900_B33","doi-asserted-by":"crossref","DOI":"10.1201\/9781420010138","volume-title":"Measurement Error in Nonlinear Models: A Modern Perspective","author":"Carroll","year":"2006"},{"issue":"12","key":"2019122311224947900_B34","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/jth.14319","article-title":"Clinically relevant differences between assays for von Willebrand factor activity","volume":"16","author":"Boender","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4147\/1549819\/advancesadv2019000863.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4147\/1549819\/advancesadv2019000863.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:24:36Z","timestamp":1577103876000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/24\/4147\/429645\/von-Willebrand-factor-and-factor-VIII-levels-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":34,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000863","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]}}}